Manufacturers of OTC NSAIDs marketed in the US will be required to change labeling to more strongly warn against using the drugs during the last three months of pregnancy because the ingredients may cause problems in the unborn child or complications during delivery.
The Food and Drug Administration on 15 October announced in a Drug Safety Communication that it is requiring labeling changes for Rx as well as nonprescription nonsteroidal anti-inflammatory drugs due to the risk of rare but serious kidney problems in an unborn baby, which can lead to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?